
Updated trial data shows promising disease control with TransCode's cancer therapy TTX-MC138.
TransCode Therapeutics announced updated Phase 1a trial results for TTX-MC138, an RNA-based cancer therapy targeting advanced solid tumors. Among 14 evaluable patients, 71.4% achieved stable disease, with over half maintaining control through three m...





